CDC Releases Guideline for Opioid Prescribing

The guideline is intended for primary care providers who are treating adult patients for chronic pain -- and not for active cancer treatment, palliative care, and end-of-life care.

CDC's new Guideline for Prescribing Opioids for Chronic Pain has been published in the Morbidity and Mortality Weekly Report Recommendations and Reports, and it offers recommendations to improve patients' safety and care for those with chronic pain while addressing the prescription opioid overdose epidemic.

From 1999 to 2014, more than 165,000 people in the United States died from overdoses related to prescription opioids, according to the agency, which reports that prescribing and sales of opioids have quadrupled since 1999 "without a change in the amount of pain Americans report."

The guideline is intended for primary care providers who are treating adult patients for chronic pain -- and not for active cancer treatment, palliative care, and end-of-life care. Its recommendations include:

  • Non-opioid therapy is preferred for chronic pain outside of active cancer treatment, palliative care, and end-of-life care.
  • When opioids are used, providers should prescribe the lowest effective dosage.
  • Providers should work with patients to establish pain treatment goals, check for improvements in pain and function regularly, and taper or discontinue opioids if a patient experiences harm.

The guideline addresses: 1) when to initiate or continue opioids for chronic pain; 2) opioid selection, dosage, duration, follow-up, and discontinuation; and 3) assessing risk and addressing harms of opioid use. CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.

Product Showcase

  • The MGC Simple Plus

    The MGC Simple Plus is a simple-to-use, portable multi gas detector that runs continuously for three years without being recharged or routinely calibrated after its initial charge and calibration during manufacturing. The detector reliably tests a worksite’s atmosphere for hydrogen sulfide, carbon monoxide, oxygen and combustible gases (LEL). Its durability enables the detector to withstand the harshest treatment and environments, hence earning it an IP 68 rating. The MGC Simple Plus is also compatible with a variety of accessories, such as the GCT External Pump. Visit gascliptech.com for more information. Read More

  • Full Line of Defense Against Combustible Dust Nilfisk

    Nilfisk provides a comprehensive range of industrial vacuums meticulously crafted to adhere to NFPA 652 housekeeping standards, essential for gathering combustible dust in Class I, Group D, and Class II, Groups E, F & G environments or non-classified settings. Our pneumatic vacuums are meticulously engineered to fulfill safety criteria for deployment in hazardous surroundings. Leveraging advanced filtration technology, Nilfisk ensures the secure capture of combustible materials scattered throughout your facility, ranging from fuels, solvents, and metal dust to flour, sugar, and pharmaceutical powders. Read More

  • SwabTek® Cannabis Test Kit

    The SwabTek® Cannabis Test Kit is a single-use spot test designed for use in screening for cannabis compounds in any sample type or on any surface. The test is capable of identifying the presumed presence of cannabinoids in very small quantities, with a level of detection as little as 6 μg in mass. Learn more about the SwabTek® Cannabis Test Kit and the rest of SwabTek surface drug testing solutions through the webinar titled "Everything You Want To Know About Surface Testing" Read More

Featured

Artificial Intelligence